EGFR mutations and the terminal respiratory unit

Cancer and Metastasis Reviews

Volumn 29, Issue 1, 2010, Pages 23-36

  Yatabe, Yasushi ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Adenocarcinoma; EGFR mutation; Lung cancer; Molecular classification; Terminal respiratory unit

Indexed keywords

B RAF KINASE; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PACLITAXEL; THYMOID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACINAR CELL CARCINOMA; ASIAN; CANCER CLASSIFICATION; CANCER RESISTANCE; COLORECTAL CANCER; GENE ACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MUCINOUS CARCINOMA; MUTATIONAL ANALYSIS; PAPILLARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SMOKING HABIT; TERMINAL RESPIRATORY UNIT; TUMOR LOCALIZATION; TUMOR PROMOTION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; SMOKING; TERMINALLY ILL; TREATMENT FAILURE;

EID: 77349124901     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9205-8     Document Type: Review

References (122)

1. FR Hirsch GV Scagliotti CJ Langer M Varella-Garcia WA Franklin 2003 Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies Lung Cancer 41 Suppl 1 S29 S42 12867060
2. CD Thienelt PA Bunn Jr N Hanna A Rosenberg MN Needle ME Long, et al. 2005 Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer Journal of Clinical Oncology 23 8786 8793 16246975
3. E Kim A Mauer F Fossella TA Jamison MS Kies KM Pisters BS Glisson GRJ Blumenschein RG Zinner HT Tran P Windt D Liu F Khuri K Dicke M Needle EE Vokes WK Hong RS Herbst 2002 A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC) Proceedings of the American Society Clinical Oncology 21 (abstr 1168) 293
4. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard, et al. 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer Journal of Clinical Oncology 21 2237 2246 12748244
5. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani, et al. 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial Jama 290 2149 2158 14570950
6. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New England Journal of Medicine 350 2129 2139 15118073
7. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125
8. JD Minna AF Gazdar SR Sprang J Herz 2004 Cancer. A bull's eye for targeted lung cancer therapy Science 304 1458 1461 15178790
9. IB Weinstein 2002 Cancer. Addiction to oncogenes-the Achilles heal of cancer Science 297 63 64 12098689
10. H Shigematsu AF Gazdar 2006 Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers International Journal of Cancer 118 257 262
11. T Mitsudomi Y Yatabe 2007 Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Science 98 1817 1824 17888036
12. H Greulich TH Chen W Feng PA Janne JV Alvarez M Zappaterra, et al. 2005 Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants PLoS Med 2 e313 16187797
13. GJ Riely W Pao D Pham AR Li N Rizvi ES Venkatraman, et al. 2006 Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clinical Cancer Research 12 839 844 16467097
14. DM Jackman BY Yeap LV Sequist N Lindeman AJ Holmes VA Joshi, et al. 2006 Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib Clinical Cancer Research 12 3908 3914 16818686
15. T Mitsudomi T Kosaka H Endoh Y Horio T Hida S Mori, et al. 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence Journal of Clinical Oncology 23 2513 2520 15738541
16. Y Yatabe T Mitsudomi 2007 Epidermal growth factor receptor mutations in lung cancers Pathology International 57 233 244 17493170
17. A Marchetti L Felicioni F Buttitta 2006 Assessing EGFR mutations New England Journal of Medicine 354 526 528 16452569 author reply -8
18. N Thatcher A Chang P Parikh J Rodrigues Pereira T Ciuleanu J von Pawel, et al. 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537 16257339
19. SW Han TY Kim PG Hwang S Jeong J Kim IS Choi, et al. 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib Journal of Clinical Oncology 23 2493 2501 15710947
20. A Bezjak D Tu L Seymour G Clark A Trajkovic M Zukin, et al. 2006 Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 Journal of Clinical Oncology 24 3831 3837 16921034
21. M Ando I Okamoto N Yamamoto K Takeda K Tamura T Seto, et al. 2006 Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib Journal of Clinical Oncology 24 2549 2556 16735708
22. F Ciardiello F De Vita M Orditura G Tortora 2004 The role of EGFR inhibitors in nonsmall cell lung cancer Current Opinion in Oncology 16 130 135 15075904
23. C Ho N Murray J Laskin B Melosky H Anderson G Bebb 2005 Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America Lung Cancer 49 225 231 15925429
24. AS Tsao XM Tang B Sabloff L Xiao H Shigematsu J Roth, et al. 2006 Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer Journal of Thoracic Oncol 1 231 239 (Pubitemid 47181440)
25. M Nomura H Shigematsu L Li M Suzuki T Takahashi P Estess, et al. 2007 Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers PLoS Med 4 e125 17455987
26. S Krishnaswamy R Kanteti JS Duke-Cohan S Loganathan W Liu PC Ma, et al. 2009 Ethnic differences and functional analysis of MET mutations in lung cancer Clinical Cancer Research 15 5714 5723 19723643
27. N Nose K Sugio T Oyama T Nozoe H Uramoto T Iwata, et al. 2009 Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung Journal of Clinical Oncology 27 411 417 19064969
28. MG Raso C Behrens MH Herynk S Liu L Prudkin NC Ozburn, et al. 2009 Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation Clinical Cancer Research 15 5359 5368 19706809
29. LP Stabile JS Lyker CT Gubish W Zhang JR Grandis JM Siegfried 2005 Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects Cancer Research 65 1459 1470 15735034
30. K Matsuo H Ito Y Yatabe A Hiraki K Hirose K Wakai, et al. 2007 Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese Cancer Science 98 96 101 17054433
31. T Kosaka Y Yatabe H Endoh H Kuwano T Takahashi T Mitsudomi 2004 Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Research 64 8919 8923 15604253
32. D Pham MG Kris GJ Riely IS Sarkaria T McDonough S Chuai, et al. 2006 Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas Journal of Clinical Oncology 24 1700 1704 16505411
33. M Seike A Goto T Okano ED Bowman AJ Schetter I Horikawa, et al. 2009 MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers Proceedings of the National Academy of Sciences of the United States of America 106 12085 12090 19597153
34. S Toyooka K Matsuo H Shigematsu T Kosaka M Tokumo Y Yatabe, et al. 2007 The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer Clinical Cancer Research 13 5763 5768 17908966 (Pubitemid 47583901)
35. T Tanaka M Matsuoka A Sutani A Gemma M Maemondo A Inoue S Okinaga M Nagashima S Oizumi K Uematsu Y Nagai G Moriyama H Miyazawa K Ikebuchi S Morita K Kobayashi K Hagiwara 2009 Frequency of and variables associated with the EGFR mutation and its subtypes Int J Cancer 126 651 655
36. S Kobayashi TJ Boggon T Dayaram PA Janne O Kocher M Meyerson, et al. 2005 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib New England Journal of Medicine 352 786 792 15728811 (Pubitemid 40271173)
37. W Pao VA Miller KA Politi GJ Riely R Somwar MF Zakowski, et al. 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 e73 15737014
38. T Kosaka Y Yatabe H Endoh K Yoshida T Hida M Tsuboi, et al. 2006 Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib Clinical Cancer Research 12 5764 5769 17020982
39. MN Balak Y Gong GJ Riely R Somwar AR Li MF Zakowski, et al. 2006 Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clinical Cancer Research 12 6494 6501 17085664
40. J Bean GJ Riely M Balak JL Marks M Ladanyi VA Miller, et al. 2008 Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma Clinical Cancer Research 14 7519 7525 19010870
41. JA Engelman T Mukohara K Zejnullahu E Lifshits AM Borras CM Gale, et al. 2006 Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer Journal of Clinical Investigation 116 2695 2706 16906227
42. JA Engelman K Zejnullahu T Mitsudomi Y Song C Hyland JO Park, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039 1043 17463250
43. S Yano W Wang Q Li K Matsumoto H Sakurama T Nakamura, et al. 2008 Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Research 68 9479 9487 19010923
44. P Laurent-Puig A Cayre G Manceau E Buc JB Bachet T Lecomte P Rougier A Lievre B Landi V Boige M Ducreux M Ychou F Bibeau O Bouche J Reid S Stone F Penault-Llorca 2009 Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer Journal of Clinical Oncology 27 5924 5930 19884556
45. F Loupakis L Pollina I Stasi A Ruzzo M Scartozzi D Santini, et al. 2009 PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer Journal of Clinical Oncology 27 2622 2629 19398573
46. M Frattini P Saletti E Romagnani V Martin F Molinari M Ghisletta, et al. 2007 PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients British Journal of Cancer 97 1139 1145 17940504
47. ML Sos M Koker BA Weir S Heynck R Rabinovsky T Zander, et al. 2009 PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Cancer Research 69 3256 3261 19351834
48. A Marchetti M Milella L Felicioni F Cappuzzo L Irtelli M Del Grammastro, et al. 2009 Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones Neoplasia 11 1084 1092 19794967
49. BP Coe WW Lockwood L Girard R Chari C Macaulay S Lam, et al. 2006 Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer British Journal of Cancer 94 1927 1935 16705311 (Pubitemid 43882587)
50. T Cerny DM Barnes P Hasleton PV Barber K Healy W Gullick, et al. 1986 Expression of epidermal growth factor receptor (EGF-R) in human lung tumours British Journal of Cancer 54 265 269 3017396
51. RE Sobol RW Astarita C Hofeditz H Masui R Fairshter I Royston, et al. 1987 Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody Journal of the National Cancer Institute 79 403 407 3476783
52. A Tatematsu J Shimizu Y Murakami Y Horio S Nakamura T Hida, et al. 2008 Epidermal growth factor receptor mutations in small cell lung cancer Clinical Cancer Research 14 6092 6096 18829487
53. MF Zakowski M Ladanyi MG Kris 2006 EGFR mutations in small-cell lung cancers in patients who have never smoked New England Journal of Medicine 355 213 215 16837691
54. I Okamoto J Araki R Suto M Shimada K Nakagawa M Fukuoka 2006 EGFR mutation in gefitinib-responsive small-cell lung cancer Annals of Oncology 17 1028 1029 16357019
55. DW Bell I Gore RA Okimoto N Godin-Heymann R Sordella R Mulloy, et al. 2005 Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR Nature Genetics 37 1315 1316 16258541
56. K Ikeda H Nomori T Mori J Sasaki T Kobayashi 2008 Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer Annals of Thoracic Surgery 85 1430 1432 18355544
57. AG Pallis A Voutsina A Kalikaki J Souglakos E Briasoulis S Murray, et al. 2007 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer British Journal of Cancer 97 1560 1566 18000506
58. JL Marks B Golas T Kirchoff VA Miller GJ Riely K Offit, et al. 2008 EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations Journal of Thoracic Oncology 3 805 18594331
59. I Schwentner M Witsch-Baumgartner GM Sprinzl J Krugmann A Tzankov S Jank, et al. 2008 Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck Head and Neck 30 1040 1044 18528899
60. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli L Bemis, et al. 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer Journal of the National Cancer Institute 97 643 655 15870435 (Pubitemid 40812628)
61. FR Hirsch M Varella-Garcia J McCoy H West AC Xavier P Gumerlock, et al. 2005 Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study Journal of Clinical Oncology 23 6838 6845 15998906
62. MS Tsao A Sakurada JC Cutz CQ Zhu S Kamel-Reid J Squire, et al. 2005 Erlotinib in lung cancer-molecular and clinical predictors of outcome New England Journal of Medicine 353 133 144 16014883
63. J Gandhi J Zhang Y Xie J Soh H Shigematsu W Zhang, et al. 2009 Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines PLoS ONE 4 e4576 19238210
64. J Soh N Okumura WW Lockwood H Yamamoto H Shigematsu W Zhang, et al. 2009 Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells PLoS ONE 4 e7464 19826477
65. B Modrek L Ge A Pandita E Lin S Mohan P Yue, et al. 2009 Oncogenic activating mutations are associated with local copy gain Molecular Cancer Research 7 1244 1252 19671679
66. L Schmidt FM Duh F Chen T Kishida G Glenn P Choyke, et al. 1997 Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nature Genetics 16 68 73 9140397
67. AJ Bass H Watanabe CH Mermel S Yu S Perner RG Verhaak, et al. 2009 SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas Nature Genetics 41 1238 1242 19801978
68. Y Shimosato M Noguchi Y Matsuno 1993 Adenocarcinoma of the lung: its development and malignant progression Lung Cancer 9 99 108
69. II Wistuba AF Gazdar 2006 Lung cancer preneoplasia Annual Review of Pathology 1 331 348 18039118
70. Y Yatabe T Kosaka T Takahashi T Mitsudomi 2005 EGFR mutation is specific for terminal respiratory unit type adenocarcinoma American Journal of Surgical Pathology 29 633 639 15832087
71. Y Yatabe T Takahashi T Mitsudomi 2008 Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer Cancer Research 68 2106 2111 18381415
72. J Soh S Toyooka S Ichihara H Asano N Kobayashi H Suehisa, et al. 2008 Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung Journal of Thoracic Oncology 3 340 347 18379350
73. X Tang M Varella-Garcia AC Xavier E Massarelli N Ozburn C Moran, et al. 2008 Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas Cancer Prevention Research (Philadelphia, PA) 1 192 200
74. LM Sholl BY Yeap AJ Iafrate AJ Holmes-Tisch YP Chou MT Wu, et al. 2009 Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers Cancer Research 69 8341 8348 19826035
75. AF Gazdar JD Minna 2008 Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops Cancer Prevention Research (Philadelphia, Pa.) 1 156 60
76. JJ Abbott M Erickson-Johnson X Wang AG Nascimento AM Oliveira 2006 Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans Modern Pathology 19 1512 1518 16980946
77. ZH Li J Zheng LM Weiss D Shibata 1994 c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung American Journal of Pathology 144 303 309 8311114
78. K Taniguchi J Okami K Kodama M Higashiyama K Kato 2008 Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib Cancer Science 99 929 935 18325048
79. A Sakurada H Lara-Guerra N Liu FA Shepherd MS Tsao 2008 Tissue heterogeneity of EGFR mutation in lung adenocarcinoma Journal of Thoracic Oncology 3 527 529 18449007
80. H Nakano H Soda M Takasu N Tomonaga H Yamaguchi K Nakatomi, et al. 2008 Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule Lung Cancer 60 136 140 17889960
81. N Motoi J Szoke GJ Riely VE Seshan MG Kris VW Rusch, et al. 2008 Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes. EGFR mutations and gene expression analysis American Journal of Surgical Pathology 32 810 827 18391747
82. H Ninomiya M Hiramatsu K Inamura K Nomura M Okui T Miyoshi S Okumura Y Satoh K Nakagawa M Nishio T Horai S Miyata E Tsuchiya M Fukayama Y Ishikawa 2008 Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type Lung Cancer 63 2 235 240 18571764
83. C Chantranuwat V Sriuranpong N Huapai T Chalermchai K Leungtaweeboon N Voravud, et al. 2005 Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation J Med Assoc Thai 88 Suppl 4 S322 S329 16623049
84. K Ohtsuka H Ohnishi G Furuyashiki H Nogami Y Koshiishi A Ooide, et al. 2006 Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma Journal of Thoracic Oncology 1 787 795 17409961 (Pubitemid 47181383)
85. VA Miller MG Kris N Shah J Patel C Azzoli J Gomez, et al. 2004 Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer Journal of Clinical Oncology 22 1103 1109 15020612
86. H Blons JF Cote D Le Corre M Riquet E Fabre-Guilevin P Laurent-Puig, et al. 2006 Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation American Journal of Surgical Pathology 30 1309 1315 17001163
87. ME Garber OG Troyanskaya K Schluens S Petersen Z Thaesler M Pacyna-Gengelbach, et al. 2001 Diversity of gene expression in adenocarcinoma of the lung Proceedings of the National Academy of Sciences of the United States of America 98 13784 13789 11707590
88. A Bhattacharjee WG Richards J Staunton C Li S Monti P Vasa, et al. 2001 Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Proceedings of the National Academy of Sciences of the United States of America 98 13790 13795 11707567
89. AC Borczuk L Gorenstein KL Walter AA Assaad L Wang CA Powell 2003 Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways American Journal of Pathology 163 1949 1960 14578194
90. S Tomida K Koshikawa Y Yatabe T Harano N Ogura T Mitsudomi, et al. 2004 Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients Oncogene 23 5360 5370 15064725
91. T Takeuchi S Tomida Y Yatabe T Kosaka H Osada K Yanagisawa, et al. 2006 Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors Journal of Clinical Oncology 24 1679 1688 16549822
92. DG Beer SL Kardia CC Huang TJ Giordano AM Levin DE Misek, et al. 2002 Gene-expression profiles predict survival of patients with lung adenocarcinoma Nature Medicine 8 816 824 12118244
93. T Shibata S Hanada A Kokubu Y Matsuno H Asamura T Ohta, et al. 2007 Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma Cancer Science 98 985 991 17459062
94. DN Hayes S Monti G Parmigiani CB Gilks K Naoki A Bhattacharjee, et al. 2006 Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts Journal of Clinical Oncology 24 5079 5090 17075127
95. AC Borczuk HK Kim HA Yegen RA Friedman CA Powell 2005 Lung adenocarcinoma global profiling identifies type II transforming growth factor-(beta) receptor as a repressor of invasiveness American Journal of Respiratory and Critical Care Medicine 172 729 737 15976377
96. S Kimura Y Hara T Pineau P Fernandez-Salguero CH Fox JM Ward, et al. 1996 The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary Genes and Development 10 60 69 8557195
97. Yatabe, Y. (2004). Role of thyroid transcription Facotr-1 in pulmonary adenocarcinoma. In M. A. Hayat (Ed.), Handbook of immunohistochemistry and in situ hybridization of human carcinomas - molecular genetics; lung and breast carcinomas. Burlington: Elsevier Inc.
98. Y Yatabe T Mitsudomi T Takahashi 2002 TTF-1 expression in pulmonary adenocarcinomas American Journal of Surgical Pathology 26 767 773 12023581
99. CF Kim EL Jackson AE Woolfenden S Lawrence I Babar S Vogel, et al. 2005 Identification of bronchioalveolar stem cells in normal lung and lung cancer Cell 121 823 835 15960971
100. Y Yatabe 2006 Molecular classification of tumors with special reference to EGFR mutation in lung cancer Cancer Chemotherapy and Pharmacology 58 Suppl 1 17 23
101. GJ Breedveld JW van Dongen C Danesino A Guala AK Percy LS Dure 2002 Mutations in TITF-1 are associated with benign hereditary chorea. Human Molecular Genetics 11 971 979 11971878
102. I Ben-Porath MW Thomson VJ Carey R Ge GW Bell A Regev 2008 An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors Nature Genetics 40 499 507 18443585
103. M Widschwendter H Fiegl D Egle E Mueller-Holzner G Spizzo C Marth 2007 Epigenetic stem cell signature in cancer Nature Genetics 39 157 158 17200673
104. SA Yousem M Nikiforova Y Nikiforov 2008 The histopathology of BRAF-V600E-mutated lung adenocarcinoma American Journal of Surgical Pathology 32 1317 1321 18636014
105. F Buttitta F Barassi G Fresu L Felicioni A Chella D Paolizzi, et al. 2006 Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features International Journal of Cancer 119 2586 2591
106. K Inamura K Takeuchi Y Togashi S Hatano H Ninomiya N Motoi, et al. 2009 EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset Modern Pathology 22 508 515 19234440
107. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602
108. JD Brenton LA Carey AA Ahmed C Caldas 2005 Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Journal of Clinical Oncology 23 7350 7360 16145060
109. B Iacopetta 2002 Are there two sides to colorectal cancer? International Journal of Cancer 101 403 408
110. K Birkenkamp-Demtroder SH Olesen FB Sorensen S Laurberg P Laiho LA Aaltonen, et al. 2005 Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid Gut 54 374 384 15710986
111. L Shen M Toyota Y Kondo E Lin L Zhang Y Guo, et al. 2007 Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer Proceedings of the National Academy of Sciences of the United States of America 104 18654 18659 18003927
112. S Sun JH Schiller AF Gazdar 2007 Lung cancer in never smokers-a different disease Nature Reviews 7 778 790 17882278
113. T Takano Y Ohe H Sakamoto K Tsuta Y Matsuno U Tateishi, et al. 2005 Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer Journal of Clinical Oncology 23 6829 6837 15998907
114. M Varella-Garcia T Mitsudomi Y Yatabe T Kosaka E Nakajima AC Xavier, et al. 2009 EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort Journal of Thoracic Oncology 4 318 325 19247083
115. MJ Ahn BB Park JS Ahn SW Kim HT Kim JS Lee, et al. 2008 Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clinical Cancer Research 14 3860 3866 18559606
116. VA Miller GJ Riely MF Zakowski AR Li JD Patel RT Heelan, et al. 2008 Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib Journal of Clinical Oncology 26 1472 1478 18349398
117. AR Li D Chitale GJ Riely W Pao VA Miller MF Zakowski, et al. 2008 EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression Journal of Molecular Diagnostics 10 242 248 18403609
118. T Yokoyama M Kondo Y Goto T Fukui H Yoshioka K Yokoi, et al. 2006 EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification Cancer Science 97 753 759 16863509
119. F Pinter J Papay A Almasi Z Sapi E Szabo M Kanya, et al. 2008 Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry Journal of Molecular Diagnostics 10 160 168 18258923
120. H Sasaki S Shimizu K Okuda O Kawano H Yukiue M Yano, et al. 2009 Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer Lung Cancer 64 295 300 19058870
121. LM Sholl A John Iafrate YP Chou MT Wu YG Goan L Su, et al. 2007 Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma Modern Pathology 20 1028 1035 17673923
122. T Sone K Kasahara H Kimura K Nishio M Mizuguchi Y Nakatsumi, et al. 2007 Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer Cancer 109 1836 1844 17387741